Interleukin-6-174G>C Gene Promoter Polymorphism and Prognosis in Patients with Cancer

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 May 27

PMID 28548958

Citations 9

Authors

Kan Zhai

Yong Yang

Zhi-Gang Gao

Jie Ding

Affiliations

Soon will be listed here.

Abstract

Interleukin-6 (IL-6) is known to be involved in the pathogenesis of cancer progression. IL-6-174G>C polymorphism has shown several results in association studies. In this study, we evaluated the association the IL-6-174G>C polymorphism and overall survival (OS) of cancer using 17 eligible studies with 4,304 patients. Our meta-analysis indicated that IL-6-174G>C polymorphism is not associated with OS when assessed using 3 genotype comparison including GG/(GC+CC), CC/(GC+GG) and CC/GG. Interestingly, compared to GG carrier, patients with IL-6-174GC genotype showed a decreased hazard of poor OS (hazard ratio = 0.81, 95% confidence interval: 0.68-0.96, P = 0.018; I2 = 34.5%, Phet = 0.107). However, for GG/(GC+CC) genotype comparison, this SNP is affect patients' OS obviously in bladder cancer, ovarian and peritoneal cancer, neuroblastoma, gastric cancer and osteosarcoma, though pooled results showing negative association because adverse and protective effect on different type of cancer balance each other. These results suggest IL-6-174G>C polymorphism might play a role in modulating OS in different type of cancer and might contribute to individual treatment in the future.

Citing Articles

Association of interleukin6 rs1800796 gene polymorphism and serum level with bladder cancer in Egyptian population.

Mukhlif R, Abol-Enein H, Elsaid A, Abdelkhalek M, Khatab H, Youssef M Mol Biol Rep. 2024; 51(1):815.

PMID: 39009695 DOI: 10.1007/s11033-024-09791-0.

Impact of IL-6 and IL-1β Gene Variants on Non-small-cell Lung Cancer Risk in Egyptian Patients.

Metwally Y, Elsaid A, Elsadda R, Refaat S, Zahran R Biochem Genet. 2023; 62(5):3367-3388.

PMID: 38103126 PMC: 11427554. DOI: 10.1007/s10528-023-10596-2.

Evaluation the -174G>C Genetic Polymorphism of Interleukin-6 in Iranian Patients with Chronic Lymphocytic Leukemia.

Rostamzadeh Khameneh Z, Mohammadian M, Eishi Oskuie A, Asghari R, Nemati M Iran J Pathol. 2023; 18(4):392-397.

PMID: 38024543 PMC: 10646739. DOI: 10.30699/IJP.2023.544600.2790.

Association of IL-6 -174G>C and -572G>C Polymorphisms with Susceptibility to Cervical Cancer and Ovarian Cancer.

Hashemzehi A, Karimi-Zarchi M, Parsaeian S, Asadian F, Golestanpour H, Setayesh S Asian Pac J Cancer Prev. 2021; 22(9):2867-2871.

PMID: 34582655 PMC: 8850876. DOI: 10.31557/APJCP.2021.22.9.2867.

Effects of the IL6 -174G>C promoter polymorphism and IL-6 serum levels on the progression of cutaneous malignant melanoma.

Vlaykova T, Kurzawski M, Tacheva T, Dimov D, Anastasov A, Vlaykova D Oncol Lett. 2020; 20(2):1781-1791.

PMID: 32724421 PMC: 7377025. DOI: 10.3892/ol.2020.11740.

References

Lopez R, Zago M, Eluf-Neto J, Curado M, Daudt A, da Silva-Junior W . Education, tobacco smoking, alcohol consumption, and IL-2 and IL-6 gene polymorphisms in the survival of head and neck cancer. Braz J Med Biol Res. 2011; 44(10):1006-12. DOI: 10.1590/s0100-879x2011007500097. View

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View

Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin J, Humphries S . The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998; 102(7):1369-76. PMC: 508984. DOI: 10.1172/JCI2629. View

Leibovici D, Grossman H, Dinney C, Millikan R, Lerner S, Wang Y . Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol. 2005; 23(24):5746-56. DOI: 10.1200/JCO.2005.01.598. View

Dethlefsen C, Hojfeldt G, Hojman P . The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat. 2013; 138(3):657-64. DOI: 10.1007/s10549-013-2488-z. View

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

Parmar M, Torri V, Stewart L . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1999; 17(24):2815-34. DOI: 10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8. View

Lagmay J, London W, Gross T, Termuhlen A, Sullivan N, Axel A . Prognostic significance of interleukin-6 single nucleotide polymorphism genotypes in neuroblastoma: rs1800795 (promoter) and rs8192284 (receptor). Clin Cancer Res. 2009; 15(16):5234-9. PMC: 2740837. DOI: 10.1158/1078-0432.CCR-08-2953. View

Deans C, Rose-Zerilli M, Wigmore S, Ross J, Howell M, Jackson A . Host cytokine genotype is related to adverse prognosis and systemic inflammation in gastro-oesophageal cancer. Ann Surg Oncol. 2006; 14(2):329-39. DOI: 10.1245/s10434-006-9122-9. View

10.

Hirano T . Interleukin 6 and its receptor: ten years later. Int Rev Immunol. 1998; 16(3-4):249-84. DOI: 10.3109/08830189809042997. View

11.

Cherel M, Campion L, Bezieau S, Campone M, Charrier J, Gaschet J . Molecular screening of interleukin-6 gene promoter and influence of -174G/C polymorphism on breast cancer. Cytokine. 2009; 47(3):214-23. DOI: 10.1016/j.cyto.2009.06.011. View

12.

Williamson P, Tudur Smith C, Hutton J, Marson A . Aggregate data meta-analysis with time-to-event outcomes. Stat Med. 2002; 21(22):3337-51. DOI: 10.1002/sim.1303. View

13.

Gomes M, Coelho A, Araujo A, Azevedo A, Teixeira A, Catarino R . IL-6 polymorphism in non-small cell lung cancer: a prognostic value?. Tumour Biol. 2015; 36(5):3679-84. DOI: 10.1007/s13277-014-3006-6. View

14.

Kumari N, Dwarakanath B, Das A, Bhatt A . Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 2016; 37(9):11553-11572. DOI: 10.1007/s13277-016-5098-7. View

15.

Lippitz B, Harris R . Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis. Oncoimmunology. 2016; 5(5):e1093722. PMC: 4910721. DOI: 10.1080/2162402X.2015.1093722. View

16.

Garg R, Wollan M, Galic V, Garcia R, Goff B, Gray H . Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma. Gynecol Oncol. 2006; 103(3):793-6. PMC: 2562602. DOI: 10.1016/j.ygyno.2006.08.043. View

17.

Taga T, Kishimoto T . Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol. 1997; 15:797-819. DOI: 10.1146/annurev.immunol.15.1.797. View

18.

DeMichele A, Martin A, Mick R, Gor P, Wray L, Klein-Cabral M . Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res. 2003; 63(22):8051-6. View

19.

Iacopetta B, Grieu F, Joseph D . The -174 G/C gene polymorphism in interleukin-6 is associated with an aggressive breast cancer phenotype. Br J Cancer. 2004; 90(2):419-22. PMC: 2409577. DOI: 10.1038/sj.bjc.6601545. View

20.

Tilg H, Trehu E, Atkins M, Dinarello C, Mier J . Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood. 1994; 83(1):113-8. View